This month, Small Cap Nation's Jane King sat down with Crystal Research Associates' CEO Jeffrey Kraws to discuss the current state and future outlook of our research company. The interview, available below, also included a discussion of important trends facing the corporate research and communications industry as well as factors impacting some of the industries we serve (e.g., healthcare).
Tomorrow kicks off one of the year’s largest oncology conferences: the American Society of Clinical Oncology (ASCO) Annual Meeting, held this year over June 3-7 at McCormick Place in Chicago. With over 30,000 attendees and hundreds of presenting companies, the conference will undoubtedly include important clinical data announcements from the likes of Pfizer, Genentech, and others as well as give some smaller firms the opportunity to introduce novel oncology candidates. Amid the presentations and exhibitions, one topic in particular is expected to stand out: the costs of cancer care.
“Building a profile and becoming ‘known’ is a critical part of raising money…”— Erin Righetti, partnering360®
Healthcare conferences are in full swing this week in San Francisco, with attendees from companies large and small making the circuit at J.P. Morgan’s Annual Healthcare Conference, the EBD Group’s annual Biotech Showcase™, the StartUp Health Festival, and many others. From corporate presentations to strategic one-on-one meetings and even impromptu run-ins, networking opportunities abound and it is important for CEOs to be able to quickly, concisely, and effectively pitch their company to potential investors and/or partners.
In just six months, drug companies have spent $221 billion buying each other, with a lot of recent mergers being between biotech firms. So what is driving the deals? Business television show Arise Xchange sits down with Jeff Kraws, Cofounder and CEO of Crystal Research Associates, to discuss.
In the wake of a new report from the British government stating that antibiotic-resistant infections could kill 10 million people each year by the year 2050, senior pharmaceutical analyst Jeff Kraws of Crystal Research Associates sits down with host Akhtar Khan of Arise Xchange to discuss the report's projections and impacts of increasing drug resistance on the pharmaceutical industry and on consumers.
On Tuesday, October 14, Crystal Research Associates' senior pharmaceutical analyst and chief executive officer, Jeff Kraws, sat down with Andrew Schmertz, host of Arise TV's Xchange program, to discuss public and private efforts at curbing the Ebola outbreak.
The segment below is an excerpt from ARISE TV's Arise XChange news program, aired live from 5 pm to 5:30 pm on Wednesday, April 30. Host Andrew Schmertz and Crystal Research CEO and Senior Pharmaceutical Analyst Jeffrey Kraws discuss recent M&A activity in the pharmaceutical industry, including Pfizer's proposed buyout of AstraZeneca.
If you missed the "Extending Life and Limb" workshop on regenerative medicine held last week at the OneMedForum conference in San Francisco, you can watch the full panel discussion on YouTube at the link below.
If you are in San Francisco today for the JP Morgan Healthcare Conference, the Biotech Showcase, or the 7th annual OneMedForum, we welcome you to stop by the Westin San Francisco on Market Street to visit our booth and hear Crystal Research CEO Jeffrey Kraws speak on regenerative medicine.
Crystal Research Associates is pleased to announce today that we have officially launched our mobile app and our new website. Take a look around at some of the changes...it is now easier than ever to sign up for research notifications and even start a discussion with us about your business's strategic needs. We have also recently expanded our line of products and services, which is now reflected throughout the site.
On Tuesday, Jeffrey Kraws, senior pharmaceutical analyst at Crystal Research Associates, spoke with ABC News and Al Jazeera television regarding Johnson & Johnson’s $2.2 billion settlement for unlawfully marketing Risperdal, an anti-psychotic drug. Risperdal is FDA approved to treat schizophrenia but was illegally marketed to doctors and nursing homes as a treatment for elderly patients with dementia. The settlement included criminal fines totaling $485 million and civil fines of over $1.7 billion, which included payments to whistleblowers.
Mr. Kraws spoke with Al Jazeera from New York City in a live segment airing overseas shortly after 4 PM ET on Tuesday. Among other questions, Kraws explains some of the ethical and brand image ramifications of JNJ’s actions and answers how the drug giant was able to use a system of internal as well as third-party players, kickbacks, and unsubstantiated product claims put forth over the years despite repeated warnings from the FDA.
Last week, Jeff Kraws sat down with Rhonda Schaffler at Reuters to discuss opportunities and trends in the biotech space. Mr. Kraws is a veteran Wall Street sell-side analyst with more than 20 years of experience and is also cofounder and CEO of Crystal Research Associates. If you enjoyed the short clip of this interview released earlier this week, the full segment (available below) goes into more detail on individual biotech stocks and the events every investor should be watching out for.
Biotechnology--the use of living organisms or other biological systems in the manufacture of drugs or other products--has emerged as a critical sector for healthcare investors over the past several years. In 2012 alone, the biotech sector grew over 40% according to S&P Capital IQ. Biotech is expected to remain a hot market going forward, with considerable room for more growth. Last week, biotech firm Intrexon Corp. (XON-NYSE) made its IPO debut at $16/share and immediately soared 38%. Nearly double its IPO price, Intrexon opened at $29.99 this morning, August 13th.
If you will be at OneMedForumNY 2013 this week, you are invited to attend the Fund Managers Unplugged panel as veteran fund managers, including Crystal Research CEO Jeffrey Kraws, explore the state of financing in the life sciences arena and discuss the successful “picks” made during OneMedForumSF 2013 this past January.
Check out our YouTube page for video highlights from the first “Fund Managers Unplugged” event held in January 2013, which include Jeff Kraws' initial stock picks, Gilead Sciences (GILD-NASDAQ) and ISIS Pharmaceuticals (ISIS-NASDAQ), which are up 23% and 107% respectively since the first panel!